Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Natasha L. Kormanik
Observed names:
N. Kormanik,
Natasha Kormanik,
Natasha L Kormanik
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Johns Hopkins University
ORCID:
0009-0006-5709-9429
Observed ORCID:
0009-0006-5709-9429
OpenAlex ID:
A5031085992
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
2017
·
Nicole J. Gormley
, Chia-Wen Ko
, et al.
·
Clinical Cancer Research
·
32
Project facilitate: A review of the FDA oncology center of excellence expanded access pilot program.
2020
·
Natasha L Kormanik
, Mitchell Chan
, et al.
·
Journal of Clinical Oncology
·
4
FDA analysis of expanded access use in pediatric patients from 2015 to 2020.
2022
·
Elizabeth Duke
, Natasha L. Kormanik
, et al.
·
Journal of Clinical Oncology
·
2
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
2026
·
Rachel Ershler
, Xueping Zhou
, et al.
·
Clinical Cancer Research
PDF
Bridging the gap: FDA diversity-related postmarketing requirements.
2023
·
Natasha L. Kormanik
, Theresa Carioti
, et al.
·
Journal of Clinical Oncology
Trls-01. Fda Analysis of Expanded Access Use in Pediatric Patients With Cns Tumors From 2015 to 2020
2023
·
Elizabeth Duke
, Natasha Kormanik
, et al.
·
Neuro-Oncology
PDF
Should a SCT Nurse Advocate for Blood Products at the End of Life?
2011
·
A. Kellogg
, N. Kormanik
·
Transplantation and Cellular Therapy
Show more works
View as search
Works count:
7
Citation count:
38
H-index:
2
I10-index:
1
Year
Topic
Type